Gilead Sciences (GILD) Gets a Hold Rating from Robert W. Baird

Robert W. Baird analyst Brian Skorney maintained a Hold rating on Gilead Sciences (GILDResearch Report) on March 30 and set a price target of $63.00. The company’s shares closed last Thursday at $59.45, close to its 52-week low of $57.19.

According to, Skorney has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.4% and a 43.5% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gilead Sciences with a $71.24 average price target, a 18.8% upside from current levels. In a report issued on March 22, Wells Fargo also maintained a Hold rating on the stock with a $63.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.24 billion and net profit of $382 million. In comparison, last year the company earned revenue of $7.42 billion and had a net profit of $1.55 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.

Read More on GILD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More